# Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma

> **NCT05013437** · EARLY_PHASE1 · WITHDRAWN · sponsor: **Koen van Besien**

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Evomela
- **DEVICE:** Next Generation Sequencing
- **DRUG:** Prochlorperazine
- **DRUG:** Acetaminophen
- **DRUG:** Diphenhydramine

## Key facts

- **NCT ID:** NCT05013437
- **Lead sponsor:** Koen van Besien
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-09
- **Primary completion:** 2023-12
- **Final completion:** 2024-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The original principal Investigator left the institution.
- **Last updated:** 2024-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05013437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05013437, "Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05013437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*